A novel AAGAB mutation in a Peruvian family with punctate palmoplantar keratoderma

Ana C. Gómez-García1, Julio C. Salas-Alanís2,3, Nathaly Bar-Fernandez1, Rossana Mendoza-Meza1, Stephane M. Díaz-Montes1, Oscar R. Fajardo-Ramírez2✉

1Department of Dermatology, Peru National Police Hospital, Lima, Peru. 2Jalisco Dermatological Institute, Guadalajara, Mexico. 3Secretary of Health of the State of Nuevo León, Monterrey, Mexico. 4National Institute of Neoplastic Diseases, Lima, Peru. 5Instituto Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, México.

Abstract

Buschke–Fischer–Brauer (BFB) disease is a rare keratoderma characterized by multiple hyperkeratotic lesions on the palms and soles, with an autosomal dominant pattern. In several countries, some genetic alterations have been associated with this clinical entity. A 68-year-old Peruvian woman presenting with hyperkeratotic lesions on both her palms and soles was diagnosed with BFB keratoderma. After sequencing of the genes that had previously been related to this disease, a mutation (c.249C>G) that was predicted to generate a termination codon (Tyr83*) was found in the alpha and gamma adaptin binding protein P34 gene (AAGAB). After treatment with 30% urea plus 10% salicylic acid, the patient experienced an improvement in her condition. Here we report a novel mutation in the AAGAB gene of a patient diagnosed with BFB keratoderma and a treatment that improved her symptoms.

Keywords: keratoderma, mutation, AAGAB

Received: 7 September 2020 | Returned for modification: 6 January 2021 | Accepted: 5 February 2021

Introduction

Punctate palmoplantar keratoderma (PPK), also referred as Buschke–Fischer–Brauer (BFB) disease, is a very rare genetic disease characterized by punctate hyperkeratotic papules affecting the palmar and plantar skin (1). Its prevalence is estimated to be 1.17 per 100,000, and the clinical manifestations for this entity are observed between 10 and 45 years of age (2). Although the etiology remains poorly understood, the loci located at 8q24.13–8q24.21 and 15q22–15q24 have been associated with PPK. Through analysis has shown that the collagen type XIV alpha 1 chain (COL14A1) and alpha and gamma adaptin binding protein p34 (AAGAB) genes, located in these loci, respectively, present pathogenic mutations in patients diagnosed with PPK and their family members (3). The AAGAB gene codes a 315 amino-acid protein that allows interaction between the gamma-adaptin and alpha-adaptin subunits to stabilize the AP2 adaptor during clathrin-mediated endocytosis (CME) (4). To date, more than 20 mutations affecting the AAGAB gene have been reported in families from several countries such as Mexico, Japan, Ireland, and Scotland (5). Here we describe a novel mutation in the AAGAB gene in a woman diagnosed with PPK, who referred other members of her family that presented the same clinical manifestations.

Methods

After clinical examination, informed consent from the patient was obtained and a blood sample was taken in tubes containing EDTA (BD Vacutainer, Franklin Lakes, NJ, USA). DNA was isolated using the DNeasy kit from Qiagen (Hilden, Germany). The exome was sequenced with next-generation sequencing (NGS) in the Illumina NovaSeq platform using the Agilent SureSelect Clinical Research Exome v3. Three hundred paired end-run cycles with a Phred quality threshold > 30 were executed. The genetic variants detected were aligned against Homo sapiens, hg19, build 37.2, and analyzed using Variant Studio1.0 Software (Illumina Inc.). Mutation severity, on the basis of mutation effects in the amino-acid sequences, was estimated using the Sorting Intolerant From Tolerant (SIFT) and Polymorphism Phenotyping (PolyPhen) algorithms.

Case report and results

A 68-year-old Peruvian female patient was admitted for valve replacement surgery due to mitral cardiomyopathy; she also attended the department of dermatology due to hyperkeratotic lesions on both her palms and soles (Figs. 1A and 1B). The patient stated that the lesions had appeared when she was young, and she received a homemade herbal remedy that was topically applied, with no improvement at all. She also described the lesions as itchy and making it difficult for her to carry out daily activities; these inconveniences disappear when the lesions are surgically removed. She mentioned that her father and one of her brothers presented similar lesions, as well one of her daughters and one nephew (the son of her affected brother; Fig. 1C).

Physical examination revealed multiple hyperkeratotic papules and nodes with central depression and diameters ranging from 4 to 10 mm on both palms; the same characteristics were present on the soles, mostly observed in pressure areas. A skin biopsy stained with H&E showed hyper-granulosis and hyperkeratosis with a well-defined central epidermal depression (Fig. 1D). Neither the laboratory tests nor radiographies showed any subjacent pathological alteration.

Following informed consent from the patient, a blood sample was obtained, and the patient’s DNA was isolated and sequenced using NGS. Subsequent analysis of the sequenced data indicated the presence of a heterozygote substitution c.249C>G,
mapped to chromosomal region 15q22–15q24, which led to pre-
mature truncation of gene AAGAB by introduction of a new stop 
codon at amino-acid position 83 (Tyr83*), aligned with previous 
reports of AAGAB mutations causing punctate PPK type 1. Surpris-
ingly, a search in databases such as ClinVar from NCBI did not 
show any previous report of this truncated version of the AAGAB 
protein. The patient was treated topically with 30% urea plus 10% 
salicylic acid, and she showed clinical improvement.

**Discussion**

As reported by Polher et al., a deficiency of p34 caused by muta-
tions in the AAGAB gene results in hyperproliferative hyperker-
atosis due to constant activation of epidermal growth factor recep-
tor (EGFR) as a result of defective endocytosis and recycling of 
the EGFR proteins (4). In this context, Giehl et al. were the first 
to demonstrate a possible relationship between p34 and PPK (6).

Here we describe a novel stop codon mutation in the AAGAB gene 
generating a truncated version of p34 in a Peruvian woman diag-
nosed with PPK, a rare autosomal dominant disease. In addition,
the patient experienced clinical improvement after topical treat-
ment with 30% urea plus 10% salicylic acid. Poor access to the city 
where the patient lives makes it difficult to carry out a full genetic 
analysis of other members of her family, or to obtain more samples 
to carry out an extensive analysis to confirm the absence of the pro-
tein and the consequences of this.

**References**

palmoplantar keratoderma: a case report of type 1 (Buschke–Fischer–Brauer 

cal and molecular investigation of Buschke–Fischer–Brauer in consanguineous 

3. Antonio JR, Oliveira GB, Rossi NCP, Pires LGG. Exuberant clinical picture of 
Buschke–Fischer–Brauer palmoplantar keratoderma in bedridden patient. An 

for AAGAB causes clinically heterogeneous forms of punctate palmoplantar 

AAGAB gene in a Chinese family with punctate palmoplantar keratoderma. Acta 

et al. Nonsense mutations in AAGAB cause punctate palmoplantar keratoderma 